CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1980; 30:143-157
doi: 10.3322/canjclin.30.3.143
© 1980 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adrian, R. M.
Right arrow Articles by Skarin, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adrian, R. M.
Right arrow Articles by Skarin, A. T.

CA: A Cancer Journal for Clinicians, Vol 30, 143-157, Copyright © 1980 by American Cancer Society

Mucocutaneous Reactions to Antineoplastic Agents

Robert M. Adrian M.D., Antoinette F. Hood M.D.1, and Arthur T. Skarin M.D.2

1 Fellow in Dermatology and Instructor, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
2 Associate Professor of Medicine, Medical Oncology Division, Sidney Farber Cancer Institute; and Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts.

Mucocutaneous reaction patterns in patients receiving cancer therapy are not only variable, but in many instances identical patterns are produced by different pathologic mechanisms. For example, patients with leukemia or lymphoma may present with nodular skin lesions that may represent malignant infiltration, septic emboli, vasculitis, or a drug eruption. The most banal skin eruption may signal an impending or ongoing catastrophe. If one is able to make some clinical evaluation regarding the likelihood of a drug being responsible for the mucocutaneous eruption, it may help avoid further clinical or laboratory investigation and patient discomfort. Unfortunately, only a few antineoplastic agents have "characteristic" skin manifestations. If, however, these are kept in mind they may be helpful in the differential diagnosis of mucocutaneous eruptions occurring in patients treated with cancer chemotherapeutic agents.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1980 by American Cancer Society.